OncoMatch/Clinical Trials/NCT04597294
Prophylactic Preoperative HIPEC in Advanced Gastric Cancer at High Risk of Peritoneal Recurrence
Is NCT04597294 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including FLOT + HIPEC + Surgery and FLOT + Surgery for gastric cancer.
Treatment: FLOT + HIPEC + Surgery · FLOT + Surgery — The study was designed to evaluate the efficacy of perioperative FLOT chemotherapy in combination with perioperative hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced gastric cancer at high risk of peritoneal metastases. The impact of treatment on peritoneal recurrence and survival over 6 months, 1, 3 and 5 years will be assessed.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Disease stage
Required: Stage N0-3B, CM0
Advanced gastric cancer cT3 / cT4a / N0-3b. No distant metastases on computed tomography (CT) scan of the chest, abdomen and pelvis (cM0).
Performance status
ECOG/WHO 0–2
Prior therapy
Cannot have received: abdominal surgery (including oncological surgery)
Exception: laparoscopic cholecystectomy or appendectomy (open or laparoscopic)
Previous abdominal surgery (including oncological surgery), other than laparoscopic cholecystectomy or appendectomy (open or laparoscopic).
Cannot have received: systemic treatment or radiotherapy for another cancer
Systemic treatment or radiotherapy for another cancer.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify